BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33081987)

  • 41. 6-Hydroxybenzothiophene ketones: potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) owing to favorable molecule geometry and conformational preorganization.
    Miralinaghi P; Schmitt C; Hartmann RW; Frotscher M; Engel M
    ChemMedChem; 2014 Oct; 9(10):2294-308. PubMed ID: 25044709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parallel solid-phase synthesis of 3beta-peptido-3alpha-hydroxy-5alpha-androstan-17-one derivatives for inhibition of type 3 17beta-hydroxysteroid dehydrogenase.
    Maltais R; Luu-The V; Poirier D
    Bioorg Med Chem; 2001 Dec; 9(12):3101-11. PubMed ID: 11711285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
    Tchédam Ngatcha B; Luu-The V; Labrie F; Poirier D
    J Med Chem; 2005 Aug; 48(16):5257-68. PubMed ID: 16078844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.
    Allan GM; Vicker N; Lawrence HR; Tutill HJ; Day JM; Huchet M; Ferrandis E; Reed MJ; Purohit A; Potter BV
    Bioorg Med Chem; 2008 Apr; 16(8):4438-56. PubMed ID: 18329273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. C-3 Steroidal Hemiesters as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 10.
    Hanzlova M; Slavikova B; Morozovova M; Musilek K; Rotterova A; Zemanová L; Kudova E
    ACS Omega; 2024 Mar; 9(10):12116-12124. PubMed ID: 38496976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
    Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: key tools for studying and treating estrogen-dependent diseases.
    Poirier D
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):83-94. PubMed ID: 21182944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of steroidogenesis and steroidogenic enzyme functions.
    Luu-The V
    J Steroid Biochem Mol Biol; 2013 Sep; 137():176-82. PubMed ID: 23770321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and steroid sulphatase inhibitory activity of C19- and C21-steroidal derivatives bearing a benzyl-inhibiting group.
    Ciobanu LC; Boivin RP; Luu-The V; Poirier D
    Eur J Med Chem; 2001; 36(7-8):659-71. PubMed ID: 11600235
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and optimization of a new family of type 3 17 beta-hydroxysteroid dehydrogenase inhibitors by parallel liquid-phase chemistry.
    Maltais R; Luu-The V; Poirier D
    J Med Chem; 2002 Jan; 45(3):640-53. PubMed ID: 11806715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
    Bey E; Marchais-Oberwinkler S; Werth R; Negri M; Al-Soud YA; Kruchten P; Oster A; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2008 Nov; 51(21):6725-39. PubMed ID: 18855374
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved synthesis of EM-1745, preparation of its C17-ketone analogue and comparison of their inhibitory potency on 17beta-hydroxysteroid dehydrogenase type 1.
    Bérubé M; Poirier D
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):832-43. PubMed ID: 19003559
    [TBL] [Abstract][Full Text] [Related]  

  • 55. C16 and C17 derivatives of estradiol as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships.
    Sam KM; Boivin RP; Tremblay MR; Auger S; Poirier D
    Drug Des Discov; 1998 May; 15(3):157-80. PubMed ID: 9689499
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
    Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
    Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation.
    Benek O; Vaskova M; Miskerikova M; Schmidt M; Andrys R; Rotterova A; Skarka A; Hatlapatkova J; Karasova JZ; Medvecky M; Hroch L; Vinklarova L; Fisar Z; Hroudova J; Handl J; Capek J; Rousar T; Kobrlova T; Dolezal R; Soukup O; Aitken L; Gunn-Moore F; Musilek K
    Eur J Med Chem; 2023 Oct; 258():115593. PubMed ID: 37390508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
    Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
    Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
    Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV
    Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).
    Spadaro A; Negri M; Marchais-Oberwinkler S; Bey E; Frotscher M
    PLoS One; 2012; 7(1):e29252. PubMed ID: 22242164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.